Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
LEXINGTON, Mass., March 16, 2016 -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2015 on Wednesday, March 30, 2016, prior to the market open.
The Company will hold a conference call on Wednesday, March 30, 2016 at 8:30 a.m. ET to discuss the results. The dial-in numbers are 1-877-407-0784 for domestic callers and 1-201-689-8560 for international callers. The conference ID number for both is 13632696. A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com.
After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year. In addition, a telephonic replay of the call will be available until April 13, 2016. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use event passcode 13632696.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap aldehydes. Aldeyra has completed Phase IIa testing of NS2 in subjects with induced allergic conjunctivitis, and has initiated clinical testing of NS2 for the treatment of noninfectious anterior uveitis and Sjögren-Larsson Syndrome. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com
Corporate Contact: Stephen Tulipano Aldeyra Therapeutics, Inc. Tel: +1 781-761-4904 ext. 205 [email protected] Investor Contact: David Burke The Ruth Group Tel: +1 646-536-7009 [email protected]
